Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P62701
UPID:
RS4X_HUMAN
Alternative names:
40S ribosomal protein S4; SCR10; Single copy abundant mRNA protein
Alternative UPACC:
P62701; P12631; P12750; P27576; P55831; Q14727; Q6IPY4
Background:
Small ribosomal subunit protein eS4, X isoform, also known as 40S ribosomal protein S4, plays a crucial role in protein synthesis. As a component of the small ribosomal subunit, it is involved in the intricate process of translating mRNA into polypeptides, facilitating cellular function and growth. This protein is part of the SSU processome, contributing to pre-rRNA processing and ribosome assembly.
Therapeutic significance:
Understanding the role of Small ribosomal subunit protein eS4, X isoform could open doors to potential therapeutic strategies. Its involvement in fundamental cellular processes like protein synthesis positions it as a key target for research aimed at uncovering novel treatments for diseases where protein synthesis is disrupted.